Also found in: Medical, Wikipedia.


A trademark for the mesylate form of imatinib.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
References in periodicals archive ?
The company added that the ANDA for Imatinib Mesylate Tablets was developed in collaboration with Stason Pharmaceuticals Inc and is the generic version for Gleevec Tablets by Novartis.
WEDNESDAY, May 9, 2018 (HealthDay News) -- Prices of imatinib (Gleevec) remained high even after a generic version was introduced, according to a study published in the May issue of Health Affairs.
I then went to an oncologist at the Marsden who said GISTs tend to come back again, but if they did they were developing an oral anti-cancer drug called Gleevec that I could take.
In a clinical trial involving 62 patients, researchers studied the effect of the drug imatinib (brand name ( Gleevec ).
Novartis won a Prix Galien USA Best Biotechnology Product award for Cosentyx (secukinumab), a psoriasis drug, and a Prix Galien USA Discovery of the Decade Best Pharmaceutical Product award for Gleevec (imatinib mesylate), indicated for the treatment of leukemia and other cancers.
The loss of exclusivity on Glivec, or Gleevec as it is known in the US, caused net sales for the drug to tank by 25 percent in the second quarter, Novartis said.
In one memo, the embassy warns that breaking Novartis' patent for the leukemia drug Gleevec could hurt U.S.
Now 34, Todd is still in remission, taking Gleevec, a form of oral chemotherapy, every day, but appreciating what he has.
Swiss drug maker Novartis that witnessed drawn-out patent related litigations in India " first on cancer drug Gleevec and more recently on respiratory treatment Onbrez has launched Sequadra, an advanced treatment for patients with chronic respiratory issues.
Some of these drugs, including the leukemia drug Gleevec, don't work as well as expected when blood cancer cells grow in soft surroundings, bioengineers Jae-Won Shin and David Mooney of Harvard University reported December 7.
The book examines in detail the VAMP trial for children with leukaemia, the ECOG 0971 breast cancer trials and the so-called "magic bullet" Gleevec pills, with a view to how they revolutionised the study of biomedicine globally.